By Myea Curry, PHR, SHRM-CP, CPSP Senior Manager, Benefits & Compliance, Agero As benefits professionals, we're often tasked with evaluating new programs and vendors. What's discussed less often is what happens when you inherit an existing benefit. When I joined Agero's benefits team, our pharmacy navigation program was already in place. By then, I had already spent more than a decade with the company in HR and People Operations roles. I knew our workforce well, understood th

Pharmacy costs are climbing — and for most HR and benefits teams, the usual playbook of Rx cost containment strategies isn't doing enough to keep up. In a recent conversation with Jordan Counts, VP of Pharmacy Services at Quantum Health, we got into the weeds on why that is, and what a more effective approach looks like. The real problem isn't your benefits plan — it's what happens after it's designed. Most employers have put serious work into their pharmacy benefits: better

What are employers prioritizing when it comes to pharmacy benefits? That's the question I walked into — and came out of with a much clearer answer. As Scripta's Chief Pharmacy Officer, I was invited to speak at this year's Business Group on Health Pharmacy Benefit Committee (PBC) Meeting. Being in that room, on the stage and off, gives you a different kind of access to what employers are actually experiencing. Here's what I took away. GLP-1s Are Still Dominating — But the Con

Health plan leaders are asking a consistent set of questions: why pharmacy spend continues to rise despite increasingly sophisticated benefit design, why existing tools aren’t consistently influencing decisions at the point of prescribing, and where real, actionable savings are actually being left on the table. A related challenge is understanding how to drive better medication decisions earlier in the care journey without adding friction for members or providers. We’re bre

Dr. Paul S. Bradley, MD As Scripta's Chief Medical Officer and an actively practicing clinician currently participating in GLP-1 clinical trials, I've had a front-row seat to one of the most significant shifts in obesity medicine in decades. GLP-1 pills are dominating headlines right now, and while the excitement is warranted, there's a lot of nuance in the data that aren’t necessarily in the headlines. Here's my honest take on what's working, what's being misunderstood,

By Miriam Paramore, Founder & CEO of RxUtility There's never been more "transparency" in prescription drug pricing – and in some ways, plan sponsors have never been more confused. That's not a coincidence. After 35 years in healthcare technology and drug pricing policy, I've watched every transparency initiative promise to finally make the system legible for employers. And each time, the data got bigger, the reports got longer, and the fundamental question got harder to a